Inotuzumab Ozogamicin
Showing 1 - 25 of 117
Acute Lymphoblastic Leukemia Trial (inotuzumab ozogamicin)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- inotuzumab ozogamicin
- (no location specified)
Jan 6, 2023
ALL, MRD-positive, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Inotuzumab Ozogamicin)
Recruiting
- ALL
- +2 more
- Inotuzumab Ozogamicin
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jul 14, 2023
ACUTE LYMPHOBLASTIC LEUKEMIA Trial (Inotuzumab ozogamicin, ALLR3)
Not yet recruiting
- ACUTE LYMPHOBLASTIC LEUKEMIA
- Inotuzumab ozogamicin
- ALLR3
- (no location specified)
Feb 17, 2023
Patients Who Received Inotuzumab Ozogamicin for B-cell ALL That
Not yet recruiting
- Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Inotuzumab Ozogamicin
- (no location specified)
Nov 3, 2022
Leukemia Trial in Houston (Cyclophosphamide, Vincristine, Blinatumomab)
Not yet recruiting
- Leukemia
- Cyclophosphamide
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Dec 23, 2022
Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab
Not yet recruiting
- Ph+ ALL
- +2 more
- the usage of Olverembatinib combined with Inotuzumab Ozogamicin
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital, Chinese Acade
Oct 30, 2022
Precursor Cell Lymphoblastic Leukemia Trial in Germany (Inotuzumab ozogamicin)
Recruiting
- Precursor Cell Lymphoblastic Leukemia
- Inotuzumab ozogamicin
-
Augsburg, Germany
- +13 more
Oct 31, 2022
Acute Lymphocytic Leukemia Trial (Inotuzumab ozogamicin)
Not yet recruiting
- Acute Lymphocytic Leukemia
- Inotuzumab ozogamicin
- (no location specified)
Jul 11, 2022
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma Trial (Cyclophosphamide, Vincristine, Dexamethasone)
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- B Lymphoblastic Lymphoma
- Cyclophosphamide
- +10 more
- (no location specified)
Aug 2, 2022
Acute Lymphoblastic Leukemia, Hyperbilirubinemia Trial in Houston (Levocarnitine, Vitamin B Complex)
Recruiting
- Acute Lymphoblastic Leukemia
- Hyperbilirubinemia
- Levocarnitine
- Vitamin B Complex
-
Houston, TexasM D Anderson Cancer Center
Nov 7, 2022
Infective Complications and Outcome of ALL Treated With INO
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +4 more
- (no location specified)
Aug 29, 2023
Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia Trial in Chicago (Inotuzumab ozogamicin,
Recruiting
- Lymphoblastic Leukemia
- +2 more
- Inotuzumab ozogamicin
- +7 more
-
Chicago, IllinoisUniversity of Chicago Medical Center
May 16, 2022
B-cell Acute Lymphoblastic Leukemia Trial in United States (Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Inotuzumab ozogamicin
- +6 more
-
Nashville, Tennessee
- +3 more
Aug 14, 2022
Besponsa Post Marketing Surveillance Study
Active, not recruiting
- Hematologic Maligmancy
- Inotuzumab ozogamicin
-
Seoul, Korea, Republic ofPfizer
Oct 10, 2022
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,
Completed
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- +6 more
- Bosutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 25, 2022
InO - A Retrospective Study of UK Patients With Leukaemia
Completed
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Inotuzumab Ozogamicin
-
Bristol, United Kingdom
- +3 more
Jan 27, 2022
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5
Withdrawn
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- +7 more
- Inotuzumab Ozogamicin
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 13, 2022
Acute Lymphoblastic Leukemia Trial (chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- chidamide
- +2 more
- (no location specified)
Oct 19, 2023
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL Trial in Boston (Venetoclax, Dexamethasone, Inotuzumab Ozogamicin)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- Venetoclax
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 19, 2021
CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Houston (Inotuzumab
Terminated
- CD22 Positive
- +2 more
- Inotuzumab Ozogamicin
-
Houston, TexasM D Anderson Cancer Center
Mar 17, 2021
Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma, ACUTE LYMPHOBLASTIC LEUKEMIA Trial in Worldwide (inotuzumab
Active, not recruiting
- Leukemia
- +2 more
- inotuzumab ozogamicin-dose level 2
- Inotuzumab ozogamicin-dose level 1
-
Los Angeles, California
- +45 more
Mar 9, 2022
Acute Lymphoid Leukemia Trial in Italy (Inotuzumab Ozogamicin (IO))
Recruiting
- Acute Lymphoid Leukemia
- Inotuzumab Ozogamicin (IO)
-
Ancona, Italy
- +29 more
Dec 31, 2021
Trial (Inotuzumab Ozogamicin)
Approved for marketing
- Inotuzumab Ozogamicin
- (no location specified)
May 14, 2020
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial in
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Biospecimen Collection
- +11 more
-
Birmingham, Alabama
- +152 more
Jan 30, 2023
Acute Lymphoblastic Leukemia Trial (Tisagenlecleucel, Blinatumomab, Inotuzumab)
Withdrawn
- Acute Lymphoblastic Leukemia
- Tisagenlecleucel
- +2 more
- (no location specified)
Jul 7, 2020